The detection of psilocybin, the psychoactive compound in certain mushrooms, in biological samples is a complex matter. Drug tests primarily target commonly abused substances like opioids, cocaine, amphetamines, and cannabis. Standard drug screening panels rarely include assays specifically designed to identify psilocybin or its metabolites.
The primary reason for the limited availability of psilocybin drug tests lies in the relatively short detection window and the lower prevalence of its use compared to other illicit drugs. Psilocybin is rapidly metabolized by the body, making it difficult to detect for extended periods. Furthermore, from a historical perspective and in the context of workplace or legal drug testing, the demand for such testing has been limited.